From OSN Europe

MacuLogix launches AdaptDx for early AMD detection

MacuLogix Inc. has launched AdaptDx in Europe at the Euretina meeting in Vienna.

The dark adaptometer is designed for clinical use to detect age-related macular degeneration at a subclinical stage before structural changes in the retina are visible, according to a company press release.

“Our technology and support can enable earlier diagnosis of age-related macular degeneration, when intervention and treatment are most effective,” MacuLogix president and CEO William McPhee said. “Not only can the routine use of the AdaptDx help prevent blindness caused by AMD, we also believe it has the potential to relieve the societal costs associated with preventable vision loss in an aging population.”

 

 

MacuLogix Inc. has launched AdaptDx in Europe at the Euretina meeting in Vienna.

The dark adaptometer is designed for clinical use to detect age-related macular degeneration at a subclinical stage before structural changes in the retina are visible, according to a company press release.

“Our technology and support can enable earlier diagnosis of age-related macular degeneration, when intervention and treatment are most effective,” MacuLogix president and CEO William McPhee said. “Not only can the routine use of the AdaptDx help prevent blindness caused by AMD, we also believe it has the potential to relieve the societal costs associated with preventable vision loss in an aging population.”